Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.

about

Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model.

Item

http://www.wikidata.org/entity/Q55075934

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@en

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@nl

type

Item

label

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@en

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@nl

prefLabel

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@en

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@nl

P1476

Synergistic anti-tumor effects ...... reast cancer in a mouse model.

@en

P2093

Hulin Guo

http://www.w3.org/2001/XMLSchema#string

Jia Ren

http://www.w3.org/2001/XMLSchema#string

Ningning Song

http://www.w3.org/2001/XMLSchema#string

Suhong Hao

http://www.w3.org/2001/XMLSchema#string

Xinchao Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cell-based vaccine efficacy: aiming for hot spots

Early Diagnosis of Brain Metastases Using a Biofluids-Metabolomics Approach in Mice.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

P304

6831-6838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8188

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29731862

http://www.w3.org/2001/XMLSchema#string

P932

5920940

http://www.w3.org/2001/XMLSchema#string